Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
Blood Pharming of Red Cells.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kronstein-Wiedemann Romy, Brändle Desiree C, Künzel Stephan R, Tonn Torsten
Аннотация
BACKGROUND: The transfusion of blood is an indispensable and irreplaceable component of contemporary medicine. Nevertheless, particularly in patients with very rare blood groups, the lack of blood products still represents a significant health problem on a global scale. In order to address this shortage, strategies for producing artificial blood substitutes have been pursued for a period of time exceeding 60 years.
SUMMARY: This overview synthesizes the latest advancements in the field of erythropoiesis, encompassing the expansion strategies for erythrocyte cells, the diverse sources of ex vivo-expanded erythrocytes, the impediments to clinical implementation, the prospective applications, and alternative blood products.
CONCLUSIONS: Ex vivo generation of red blood cells (RBCs) has advanced from proof-of-concept to early clinical testing, yet scalable, cost-effective manufacturing remains unresolved. Continued optimization of cell sources, immortalized progenitor lines, and bioreactor technologies, alongside deeper mechanistic insights into terminal erythropoiesis and enucleation, will be key. Integrating these advances within rigorous regulatory frameworks could ultimately enable standardized, universally compatible RBC products.
SUMMARY: This overview synthesizes the latest advancements in the field of erythropoiesis, encompassing the expansion strategies for erythrocyte cells, the diverse sources of ex vivo-expanded erythrocytes, the impediments to clinical implementation, the prospective applications, and alternative blood products.
CONCLUSIONS: Ex vivo generation of red blood cells (RBCs) has advanced from proof-of-concept to early clinical testing, yet scalable, cost-effective manufacturing remains unresolved. Continued optimization of cell sources, immortalized progenitor lines, and bioreactor technologies, alongside deeper mechanistic insights into terminal erythropoiesis and enucleation, will be key. Integrating these advances within rigorous regulatory frameworks could ultimately enable standardized, universally compatible RBC products.